Atopic Dermatitis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

Atopic Dermatitis Drugs Market

(Albany, USA) DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atopic Dermatitis market.

Request for sample page @ Atopic Dermatitis Market Forecast

Key Takeaways from the Atopic Dermatitis Market Report

• According to DelveInsight, Atopic Dermatitis market size is expected to grow at a decent CAGR by 2034.
• Atopic Dermatitis Market Size in 7MM was around USD 17 billion in 2023, which is expected to increase by 2034.
• Leading Atopic Dermatitis Companies in the treatment market Sanofi/Regeneron Pharmaceuticals, RAPT Therapeutics, Pfizer, Japan Tobacco, and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals, and others.
• Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
• In December 2024, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced interim results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis. The findings revealed a positive safety and efficacy profile, bolstering the continued development of soquelitinib for atopic dermatitis and highlighting the potential of ITK inhibition as a new therapeutic approach for other immune-related diseases.
• In November 2024, Concerto Biosciences administered the first dose in a Phase I trial of its three-strain live biotherapeutic product, ENS-002, designed to treat atopic dermatitis. ENS-002 targets Staphylococcus aureus (S. aureus), a major contributor to skin inflammation, and is being developed to address this condition.
• In October 2024, Eli Lilly’s EBGLYSS showed significant improvement in skin condition and itch relief for patients with moderate-to-severe atopic dermatitis, as highlighted by new Phase IIIb ADapt study results. These outcomes are particularly notable for individuals who did not respond adequately to the commonly prescribed dupilumab. The 24-week, open-label Phase IIIb ADapt study evaluated the safety and efficacy of EBGLYSS in patients aged 12 to under 18 years who had previously received dupilumab treatment.
• In September 2024, Galderma has announced plans to present new findings from the ARCADIA and OLYMPIA clinical trial programs, which evaluate nemolizumab for atopic dermatitis and prurigo nodularis, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam. Scheduled for Wednesday, September 25, the presentations will include late-breaking data on long-term efficacy and safety from an interim analysis of the Phase III ARCADIA long-term extension study and novel biomarker analyses in adolescents and adults with moderate-to-severe atopic dermatitis. Additionally, Phase IIIb OLYMPIA DURABILITY study results showcasing the durability of nemolizumab’s response in adults with prurigo nodularis will also be shared.
• In August 2024, Lynk Pharmaceuticals announced promising results from its Phase Ib clinical trial of LNK01004, a novel topical therapy for atopic dermatitis. This randomized, double-blind, placebo-controlled, multicenter study evaluated the safety, tolerability, and pharmacokinetics of LNK01004 in adults with mild to moderate atopic dermatitis.
• In the 7MM, the United States had the largest market size for atopic dermatitis in 2023, with Japan following closely behind.
• DUPIXENT, the first approved therapy for atopic dermatitis (AD), generates around USD 2 billion in revenue by focusing on the moderate-to-severe patient group through targeted therapies and biologics.
• In 2023, there were approximately 53,348,000 diagnosed cases of atopic dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.
• In 2023, there were approximately 72,435,000 prevalent cases of atopic dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.
• In 2023, the total diagnosed cases of atopic dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.
• The Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atopic Dermatitis pipeline products will significantly revolutionize the Atopic Dermatitis market dynamics.The treatment in Japan for atopic dermatitis is similar to that of the US and EU4, and the UK. The Japanese market uses DUPIXENT, RINVOQ, CIBINQO, ADBRY/ADTRALZA, CORECTIM, OLUMIANT, MOIZERTO, and MITCHGA.
• April 2024: Suzhou Zelgen Biopharmaceuticals Co.,Ltd- A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic Dermatitis. This study includes a dose escalation part and a dose extension part.
• April 2024: Pfizer- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS. The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
• April 2024: Eli Lilly and Company- An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab. The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Market Outlook

Atopic Dermatitis Overview

Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It is most prevalent in children but can affect individuals of all ages. Atopic dermatitis is associated with immune system dysfunction, a compromised skin barrier, and genetic and environmental factors. Common triggers include allergens, irritants, stress, weather changes, and microbial infections.

Symptoms of Atopic dermatitis vary in severity and include redness, swelling, scaling, and oozing lesions, often occurring on the face, hands, elbows, and knees. Persistent itching can lead to scratching, worsening the condition and increasing the risk of skin infections. AD is often linked to other atopic conditions such as asthma and allergic rhinitis, known as the “atopic triad.”

Atopic dermatitis Management focuses on restoring the skin barrier, reducing inflammation, and preventing flare-ups. Treatment includes regular moisturizing, avoiding triggers, and using topical corticosteroids or calcineurin inhibitors. In moderate to severe cases, systemic treatments like biologics (e.g., dupilumab), immunosuppressants, and phototherapy may be considered.

Early Atopic dermatitis diagnosis and a personalized treatment approach are essential for improving quality of life and preventing complications. Patient education on skincare routines and trigger management plays a key role in controlling Atopic dermatitis.

Atopic Dermatitis Epidemiology Segmentation

• Atopic Dermatitis Prevalent Population
• Diagnosed Prevalent Population of Atopic Dermatitis
• Severity-specific Distribution of Atopic Dermatitis in Adults
• Severity-specific Distribution of Atopic Dermatitis in Pediatric Population
• Gender-specific Distribution of Atopic Dermatitis in Adults
• Chronic Pruritus Prevalence in Atopic Dermatitis in the adults

Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Market Dynamics

Atopic Dermatitis Emerging Drugs

Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin

Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with Atopic Dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.

Amgen and Kyowa Kirin have recently begun recruiting participants for a comprehensive, global Phase III program (ROCKET program) to investigate the safety and efficacy of rocatinlimab in a heterogeneous moderate-to-severe AD population suffering from a high burden of disease.

Atopic Dermatitis Market Dynamics

Atopic Dermatitis market to expand because of the emergence of several novel mechanisms such as oral/topical JAK Inhibitors, PDE Inhibitors, IL-13 Inhibitors, leukotriene inhibitors, Kappa opioid receptor (KOR) agonist, NK-1 receptor antagonist, and others in the upcoming market of Atopic Dermatitis and pruritus in Atopic Dermatitis. Increased public awareness, improved access to health services, reimbursements, and financial support may boost the Atopic Dermatitis and pruritus in the market and improve the Atopic Dermatitis market accessibility of the emerging drugs.

To know more about Atopic Dermatitis Therapies and Drug options, visit @ Atopic Dermatitis Treatment Market

Atopic Dermatitis Pipeline Companies

The developing pipeline of Atopic Dermatitis holds budding key players such as lebrikizumab (Eli Lilly), nemolizumab/CD14152 (Galderma), difamilast (Otsuka Pharmaceuticals), and roflumilast (Arcutis Biotherapeutics). These emerging drugs, predicted to be launched during the forecast period, are likely to change the current market dynamics of disease treatment, thereby boosting the current Atopic Dermatitis market size. Following the late-stage products, a wide array of mid-stage or Phase II promising interventions are expected to be launched soon in the Atopic Dermatitis market, including B244 (AOBiome Therapeutics), etrasimod/APD334 (Arena Pharmaceuticals), FB825 (Oneness Biotech), DS107 (DS Biopharma), bermekimab (Janssen), KY1005 (Sanofi/Kymab), and Q301 (Zileuton) (Qurient).

Learn more about the Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials and Advancements

Scope of the Atopic Dermatitis Pipeline Report

• Coverage- 7MM
• Atopic Dermatitis Companies- Sanofi (NYSE: SNY), Regeneron Pharmaceuticals (NYSE: REGN), Pfizer (NYSE: PFE), Japan Tobacco, Torii Pharmaceutical (NYSE: TRXPF), Eli Lilly and Company (NYSE: LLY), AbbVie (NYSE: ABBV), LEO Pharma, Incyte Corporation (NYSE: INCY), Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen (NYSE: JNJ), AOBiome Therapeutics, Kymab, Qurient (NYSE: KRX), Arcutis Biotherapeutics (NYSE: ARQT), Cara Therapeutics (NYSE: CARA), Vanda Pharmaceuticals (NYSE: VNDA), and others.
• Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers

Table of Content

1. Key Insights
2. Atopic Dermatitis Report Introduction
3. Atopic Dermatitis (AD) Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Atopic Dermatitis Disease Background and Overview
7. Atopic Dermatitis Epidemiology and Patient Population
8. Atopic Dermatitis Patient Journey
9. Key Endpoints in Atopic Dermatitis Clinical Trials
10. Atopic Dermatitis Marketed Therapies
11. Atopic Dermatitis Emerging Therapies
12. Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis
13. Atopic Dermatitis Market Access and Reimbursement
14. Atopic Dermatitis KOL Views
15. Atopic Dermatitis SWOT Analysis
16. Atopic Dermatitis Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting